# Irregular periods, weight and PCOS: which findings establish the diagnosis?

Body size and an insulin number do not diagnose PCOS. How reproductive features and glucose assessment answer different questions.

Canonical: https://velri.co/blog/plus-size-pcos-cycle-insulin-belly-weight-numbers-provider
Publisher: Velri (https://velri.co/about)
Published: 2026-06-20
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

Irregular periods, changes in body weight and metabolic concerns can occur with PCOS. They still need a structured assessment: body size and a fasting insulin result do not establish the diagnosis. [1][2]

## The diagnosis looks for a pattern

NICHD describes PCOS as a condition with reproductive and metabolic features. Assessment looks for a combination of ovulatory problems, excess androgens and characteristic ovarian findings. Symptoms may include irregular periods, increased facial or body hair and acne. [1]

Reproductive symptoms deserve attention even when weight is not the main concern.

## Glucose testing addresses metabolic risk

The international PCOS guideline recognizes increased risk of impaired glucose regulation and type 2 diabetes regardless of age or BMI. It recommends assessing glucose status at diagnosis and identifies an oral glucose tolerance test as the most accurate option in PCOS. [2]

If that test cannot be performed, fasting glucose or A1c can be considered, with reduced accuracy. Routine clinical insulin assays have limited usefulness and are not recommended for routine PCOS care. [2]

A result can therefore be meaningful without answering every question. Glucose testing assesses glycemic health; it does not replace the reproductive assessment.

## The treatment goal also needs a name

PCOS care may address irregular cycles, unwanted hair growth, metabolic health, weight concerns or fertility. NICHD notes that treatment varies with the symptoms and associated health problems. [1]

The guideline also emphasizes awareness of weight stigma and individualized care. [2] A useful assessment takes the menstrual history and symptoms seriously while explaining what the numbers do and do not establish.

## Sources
[1] Polycystic Ovary Syndrome (PCOS) | NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development (2026). https://www.nichd.nih.gov/health/topics/pcos
[2] Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polyendocrine Metabolic Ovarian Syndrome (2023) | American Society for Reproductive Medicine | ASRM (2023). https://www.asrm.org/practice-guidance/practice-committee-documents/recommendations-from-the-2023-international-evidence-based-guideline-for-the-assessment-and-management-of-polyendocrine-metabolic-ovarian-syndrome-2023/

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support